This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Sankyo Company, Limited. Active years: 1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991
Title: Kunio Hashi: Innovator in Pharmaceutical Freeze-Drying Technology
Introduction
Kunio Hashi is a notable inventor based in Shinagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the area of freeze-drying technology. His innovative methods have the potential to enhance the stability and efficacy of pharmaceutical compounds.
Latest Patents
Kunio Hashi holds a patent for a method of preparing a freeze-dried formulation containing a drug. This patent describes a freeze-drying method for producing a dried pharmaceutical compound or preparation. In this process, a first liquid is frozen, a second liquid is added to the frozen first liquid and is frozen thereon. The frozen first and second liquids are then freeze-dried together, with at least one of the liquids containing the pharmaceutical compound dissolved or suspended within it. The other liquid may be a pure solvent, typically water, or may contain additional substances.
Career Highlights
Throughout his career, Kunio Hashi has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Sankyo Company, Limited, where he contributed to various innovative projects. His expertise in freeze-drying technology has been instrumental in advancing pharmaceutical formulations.
Collaborations
Kunio Hashi has collaborated with several professionals in his field, including Seigo Ueda and Takashi Shiokari. These collaborations have fostered a productive exchange of ideas and have led to advancements in pharmaceutical technologies.
Conclusion
Kunio Hashi's contributions to the field of pharmaceutical freeze-drying technology are noteworthy. His innovative methods and collaborations have the potential to significantly impact the stability and delivery of pharmaceutical compounds. His work continues to inspire advancements in the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
